Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “breast cancer”

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal MetastasesRecruiting
NCT06092892Phase 2Updated Aug 10, 2026
Sponsor: Alice Chung
Breast Cancer · Axillary Nodal Disease · Female Breast Cancer · Axilla; Breast
United States
Deep Optical Imaging of Tissue (DOIT)Recruiting
NCT07754500NAUpdated Aug 10, 2026
Sponsor: Lund University
Healthy Tissue · Muscles · Extremity · Breast
Sweden
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruiting
NCT07647328Phase 3Updated Aug 10, 2026
Sponsor: AstraZeneca
ER-Positive HER2-Negative Breast Cancer
United States, France, Germany, Italy, Poland +4 more
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaRecruiting
NCT06930859N/AUpdated Aug 10, 2026
Sponsor: Novartis Pharmaceuticals
Breast Cancer
Russia
BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine TherapyRecruiting
NCT07597993N/AUpdated Aug 10, 2026
Sponsor: AstraZeneca
Breast Cancer
Oman, Qatar, Saudi Arabia, United Arab Emirates
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsRecruiting
NCT06998407Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Avenzo Therapeutics, Inc.
HR+/HER2- Breast Cancer · HR+, HER2-, Advanced Breast Cancer
United States
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Recruiting
NCT04585750Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: PMV Pharmaceuticals, Inc
Advanced Solid Tumor · Advanced Malignant Neoplasm · Metastatic Cancer · Metastatic Solid Tumor
United States, Australia, France, Germany, Italy +4 more
A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast CancerRecruiting
NCT07741968NAUpdated Aug 10, 2026
Sponsor: City of Hope Medical Center
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8 · Anatomic Stage IV Breast Cancer AJCC v8
United States
Prospective Cohort for Tumor Bed Boost Radiotherapy in HER2 Positive Breast CancerRecruiting
NCT05893966N/AUpdated Aug 10, 2026
Sponsor: Samsung Medical Center
Breast Cancer
South Korea
Supporting Health Including Endocrine Treatment for Long DurationRecruiting
NCT07482384NAUpdated Aug 10, 2026
Sponsor: Dana-Farber Cancer Institute
Breast Cancer · Breast Cancer - Female · Breast Carcinoma · ER Positive Breast Cancer
United States
Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast TissueRecruiting
NCT06127797N/AUpdated Aug 10, 2026
Sponsor: M.D. Anderson Cancer Center
Breast Cancer
United States
Medical Imaging to Re-evaluate Elacestrant Clinical UsageNot Yet Recruiting
NCT07753954Phase 2Updated Aug 10, 2026
Sponsor: Jules Bordet Institute
ER+ / HER2- Advanced Breast Cancer
5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone LossRecruiting
NCT07044310Phase 2Updated Aug 10, 2026
Sponsor: Mayo Clinic
Anatomic Stage 0 Breast Cancer AJCC v8 · Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage II Breast Cancer AJCC v8 · Anatomic Stage III Breast Cancer AJCC v8
United States
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)Recruiting
NCT05512364Phase 3Updated Aug 10, 2026
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
ER-positive Breast Cancer · HER2-negative Breast Cancer · Stage IIB Breast Cancer · Stage III Breast Cancer
Belgium, Cyprus, France, Germany, Greece +7 more
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid TumorsRecruiting
NCT07705334Phase 1Updated Aug 10, 2026
Sponsor: SHY Therapeutics
Advanced or Metastatic Solid Tumors · Triple Negative Breast Cancer (TNBC) · HR+ Breast Cancer · Colon Cancer
United States
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruiting
NCT03606967Phase 2Updated Aug 10, 2026
Sponsor: National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8 · Invasive Breast Carcinoma · Metastatic Triple-Negative Breast Carcinoma
United States
Evaluation of PSMA in HER2- AR+ Metastatic Breast CancerRecruiting
NCT04573231Phase 2Updated Aug 7, 2026
Sponsor: University of Wisconsin, Madison
Breast Cancer · HER2-negative Breast Cancer · Metastatic Breast Cancer
United States
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C MutationNot Yet Recruiting
NCT07752875Phase 1, Phase 2Updated Aug 7, 2026
Sponsor: LG Chem
Ovarian Cancer · Small Cell Lung Cancer · Non Small Cell Lung Cancer · Colorectal Cancer
LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast CancerRecruiting
NCT06831955Phase 2Updated Aug 7, 2026
Sponsor: Universitaire Ziekenhuizen KU Leuven
Triple Negative Breast Cancer (TNBC), Early Setting
Belgium
Development and Dissemination of Exercise Prescription and Intervention for Cancer PopulationsRecruiting
NCT07751783NAUpdated Aug 7, 2026
Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
Cancer · Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma) · Lung Cancer (Non-Small Cell) · Liver Cancer, Adult
Taiwan
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory MalignanciesNot Yet Recruiting
NCT07730125Phase 1, Phase 2Updated Aug 7, 2026
Sponsor: CoRegen, Inc.
HR-positive, HER2-negative Breast Cancer · TNBC - Triple-Negative Breast Cancer · Prostate Cancer
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerRecruiting
NCT06638307Phase 1Updated Aug 7, 2026
Sponsor: Stemline Therapeutics, Inc.
Advanced Breast Cancer
United States, Spain
Evaluation of a Genetic Risk Score for Lung Metastasis and Prognosis in Breast CancerNot Yet Recruiting
NCT07752966N/AUpdated Aug 7, 2026
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer Lung Metastasis
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCRecruiting
NCT07242352Phase 3Updated Aug 7, 2026
Sponsor: Women's Cancer Study Group GmbH
Breast Cancer · HR+/HER2- Breast Cancer
Germany
Endocrine Response in Women With Invasive Lobular Breast CancerCompleted
NCT02206984Phase 2Updated Aug 7, 2026
Sponsor: Priscilla McAuliffe
Breast Cancer
United States

Previous page Next page